The company’s results from its Phase 2 SB206 trial were published in the Journal of the American Academy of Dermatology.
Novan (NASDAQ:NOVN) has announced that its Phase 2 molluscum study has been published in the Journal of the American Academy of Dermatology.
As quoted in the press release:
In this Phase 2 study, SB206 demonstrated clinical efficacy with a favorable safety profile.
“The publication of this Phase 2 study through a prestigious platform such as JAAD underscores Novan’s innovative nitric-oxide technology and provides exposure to the results that supported our decision to progress into a Phase 3 molluscum program. There remains an unmet medical need for an efficacious and well-tolerated treatment that can be applied at home by patients or caregivers,” commented Tomoko Maeda-Chubachi, M.D., Ph.D., Novan’s Vice President of Medical Dermatology. Dr. Maeda-Chubachi further commented, “We look forward to reporting out the results from our Phase 3 B-SIMPLE pivotal program in the near future.”
Title: “Efficacy and Tolerability of an Investigational Nitric Oxide-releasing Topical Gel in Patients With Molluscum Contagiosum: A Randomized Clinical Trial”
Authors: Adelaide A. Hebert, Elaine C. Siegfried, Todd Durham, Emily N. de León, Teresa Reams, Elizabeth Messersmith, Tomoko Maeda-Chubachi
Publication: Journal of the American Academy of Dermatology (Available online 03 October 2019), doi: https://doi.org/10.1016/j.jaad.2019.09.064. [Epub ahead of print]
Novan continues to target top line results from the ongoing Phase 3 “B-SIMPLE” (Berdazimer Sodium In Molluscum Patients with Lesions) pivotal trials with SB206 for the treatment of molluscum no later than early in the first quarter of 2020.